Shirley, New York, Jul 7th, 2026 – Creative Bioarray, a preeminent provider of innovative solutions for biological research, is dedicated to providing a full spectrum of services and solutions to support stand-alone and integrated projects, from target discovery to candidate selection and into the clinic. Recently, Creative Bioarray is excited to announce the launch of two advanced preclinical models: the Liver Fibrosis Model and the Pulmonary Fibrosis Model. These cutting-edge platforms are specifically designed to enhance drug discovery and therapeutic development, addressing the urgent need for effective treatments in the field of liver and lung diseases.
Liver Fibrosis Model: Paving the Way for Therapeutic Innovation
Liver fibrosis, a chronic condition where scar tissue replaces healthy liver tissue, poses a significant global health challenge. It can result from various chronic liver diseases and can progress to cirrhosis or liver cancer. Creative Biorray has developed CCL4-induced, TAA-induced, and bile duct ligation-induced liver fibrosis mouse models for drug evaluation. provides researchers with invaluable tools to study liver disease mechanisms and evaluate potential drug treatments.
Creative Bioarray’s liver fibrosis models utilize various induction methods, including carbon tetrachloride (CCl4) and thioacetamide which is a well-established and widely accepted experimental model for the study of liver fibrosis and cirrhosis in order to create consistent and reproducible fibrosis in animal subjects. These models allow for the assessment of therapeutic efficacy, investigation of disease mechanisms, it mirrors the pattern of human disease associated with toxic damage and support in the development of novel interventions.
“We are committed to advancing research in liver diseases, and our liver fibrosis models are tailored to meet the unique needs of our clients,” states Hannah Cole, marketing director at Creative Bioarray. “With customizable options and robust support, we empower researchers to explore new therapeutic avenues.”
Pulmonary Fibrosis Model: A Step Forward in Lung Disease Research
Creative Bioarray offers well-characterized pulmonary fibrosis animal models to support preclinical drug efficacy evaluation, mechanistic research, and translational decision making. The portfolio includes well characterized models of idiopathic pulmonary fibrosis (IPF) and other fibrotic interstitial lung diseases, enabling clients to assess therapeutic candidates across key biological endpoints — from inflammation and fibroblast activation to extracellular matrix (ECM) deposition and impaired lung function.
Utilizing both bleomycin-induced and silica-induced models, researchers can replicate the fibrotic processes observed in human patients. These models facilitate a comprehensive evaluation of anti-fibrotic therapies, molecular targets, and pathophysiological mechanisms underlying lung fibrosis.
“With the rising incidence of pulmonary fibrosis, our innovative models serve as essential tools for drug developers,” emphasizes Brady. “They offer detailed insights into treatment effectiveness, which can ultimately lead to improved patient outcomes.”
Alongside its extensive model offerings, Creative Bioarray provides tailored research support to streamline experimental design and optimize data collection. The experienced team at Creative Bioarray is dedicated to delivering high-quality results and fostering collaboration with clients worldwide. Whether the focus is on liver injury mechanisms or the intricate dynamics of lung fibrosis, Creative Bioarray offers state-of-the-art platforms that can be adapted to meet specific research needs.
About Creative Bioarray
Creative Bioarray is dedicated to enhancing biological research with pioneering products and services designed for drug discovery, preclinical studies, and laboratory solutions. Our world-class discovery platform is backed by professional scientists, offering expertise in all major disease areas and target classes, across all therapeutic modalities.
